Retatrutide Hits Primary Endpoints in Phase 3 Type 2 Diabetes Trial
Eli Lilly's triple agonist (GIP/GLP-1/glucagon) retatrutide met its primary A1C reduction endpoint and all key secondary endpoints at 40 weeks in the TRANSCEND-T2D-1 trial.
#triple agonist
2 stories
UBT251 Triple Agonist Delivers 19.7% Weight Loss in Phase 2
Novo Nordisk and United Laboratories' new triple agonist achieved 19.7% weight loss in 24 weeks vs 2.0% placebo, intensifying competition with retatrutide.